Epidemiology of parkinson syndromes;Epidémiologie des syndromes parkinsoniens: Maladie de Parkinson, atrophie multi-systématisée et paralysie supra-nucléaire progressive

Revue Neurologique

Volumn 159, Issue 3, 2003, Pages 343-352

  Chrysostome, V ^a,b   Tison, Francois ^c,d  

^a Hop Pellegrin Tripode 4eme Etage   (France)

^b INSERM   (France)

^c Groupe Hospitalier Sud CHU de Bordeaux   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBELLUM ATROPHY; CLINICAL FEATURE; INCIDENCE; ONSET AGE; PARKINSON DISEASE; PREVALENCE; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RISK FACTOR; SURVIVAL;

ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PREVALENCE; RISK FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0345269996     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. ALBERS DS, AUGOOD SJ, PARKES LC et al. (2000). Frontal lobe dysfunction in PSP: evidence for oxidative stress and mitochondrial impairment. J Neurochem, 74: 878-881.
2. ALBERS DS, AUGOOD SJ. (2001). New insights into progressive supranuclear palsy. Trends Neurosci, 24: 347-353.
3. AQUILONIUS SM, HARTVIG P. (1986). A swedish county with unexpectedly high utilization of antiparkinsonian drugs. Acta Neurol Scand, 74: 379-382.
4. BALDERESCHI M, DI CARLO A, ROCCA WA et al. (2000). Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology, 55: 1358-63.
5. BANDMANN O, SWEENEY MG, DANIEL SE et al. (1997). Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. Neurology, 49: 1598-1604.
6. BANDMANN O, MARSDEN CD, WOOD NW. (1999). Genetic aspects of Parkinson's disease. Mov disord, 13: 203-211.
7. BANNISTER R, MOWBRAY J, SIDGWICK A. (1983). Genetic control of progressive autonomic failure: evidence for an association with an HLA antigen. Lancet, 1: 1017.
8. BEGHI E, MONTICELLI ML, SESSA A, SIMONE P, and the Italian General Practitioner Study Group (IGPSG). (1994). The prevalence of parkinsonism in Italy: an epidemiological survey of the diseases in general practice. Mov Disord, 9: 403-408.
9. BEN-SHLOMO Y, WENNING GK, TISON F, QUINN NP. (1997). Survival of patients with pathologically proven pultiple system atrophy: a meta-analysis. Neurology, 48: 384-393.
10. BERGER K, BRETELER MMB, HELMER C et al. (2000). Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology, 54 (suppl 5): S24-S27.
11. BETARBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3: 1301-1306.
12. BOWER JH, MARAGANORE DM, McDONNELL SK, ROCCA WA. (1997). Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology, 49: 1284-1288.
13. BOWER JH, MARAGANORE DM, MCDONNELL SK, ROCCA WA. (1999). Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology, 52: 1214-1220.
14. BURN DJ, MARK MH, PLAYFORD ED, MARAGANORE DM, ZIMMERMAN TR, DUVOISIN MRC. (1992). Parkinson's disease in twins studied with 18F-Dopa and positron emission tomography. Neurology, 42: 1894-1900.
15. CALNE DB. (1983). Current views of Parkinson's disease. Can J Neurol Sci, 10: 11-15.
16. CAPARROS-LEFEBVRE D, SERGEANT N, LEES A et al. (2002). Guadeloupean parkinsonism: a cluster of progressive supranuclear palsylike tauopathy. Brain, 125: 801-811.
17. CHIO A, MAGNANI C, SCHIFFER D. (1998). Prevalence of Parkinson's disease in Nothwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord, 13: 400-405.
18. COLLINS SJ, AHLSKOG JE, PARISI JE, MARAGANORE DM. (1995). Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry, 58: 167-173.
19. DAVIS GC, WILLIAMS AC, MARKEY SP. (1979). Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res, 1: 249-254.
20. DAVIS PH, GOLBE LI, DUVOISIN RC, SCHOENBERG DR. (1988). Risk factors for progressive supranuclear palsy. Neurology, 38: 1546-1552.
21. DE RIJK MC, BRETELER MMB, GRAVELAND GA et al. (1995). Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology, 45: 2143-2146.
22. DE RIJK MC, LAUNER LJ, BERGER K et al. (2000). Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology, 54: S21-S23.
23. DEXTER DT, JENNER PJ, SCHAPIRA AHV, MARSDEN CD. (1992). Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol, 32: S94-S100.
24. DICKSON DW, LIN WL, HARDY J et al. (1999). Widespread alterations of αs-synuclein in multiple system atrophy. Am J Pathol, 155: 1241-1251.
25. ELBAZ A, BOWER JH, MARAGANORE DM et al. (2002). Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol, 55: 25-31.
26. ERREA JM, ARA JR, AIBAR C, DE PEDROCUESTA J. (1999). Prevalence of Parkinson's disease in Lower Aragon, Spain. Mov Disord, 14: 596-604.
27. FALL PA, AXELSON O, FREDRIKSSON M et al. (1996). Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol, 49: 637-641.
28. FITZMAURICE PS, GUTTMAN M, KISH SJ. (2000). Evidence of oxidative stress in the substantia nigra in progressive supranuclear palsy and multiple system atrophy. Mov Disord, 15: S35.
29. FRATIGLIONI L, VIITANEN M, BACKMAN L, SANDMAN PO, WINBLAD B. (1992). Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology, 11 (suppl 1): 29-36.
30. FRUMKIN H. (1998). Multiple system atrophy following chronic carbon disulfide exposure. Environ Health Perspect, 106: 611-613.
31. GASSER T. (1998). Genetics of Parkinson's disease. Ann Neurol, 44 (suppl 1): 53-57.
32. GAZELY S, MAGUIRE J. (1994). Familial progressive supranuclear palsy. Brain Pathol, 4: 534.
33. GHORAYEB I, FERNAGUT PO, AUBERT I et al. (2000). Toward a primate model of L-Dopaunresponsive parkinsonism mimicking striatonigral degeneration. Mov Disord, 15: 531-536.
34. GIBB WRG, LEES AJ. (1988). The relevance of Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51: 745-752.
35. GILMAN S, SIMA AAF, JUNCK L et al. (1996). Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. Ann Neurol, 39: 241-255.
36. GILMAN S, LOW PA, QUINN NP, et al. (1998). Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci, 163: 94-98.
37. GIORGUIEFF-CHESSELET MF, KEMEL ML, WANDSCHEER D. (1979). Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: effect of nicotine in a low concentration. Life Sci, 25: 1257-1262.
38. GOLBE LI, CODY RA, DUVOISIN RC. (1986). Smoking and Parkinson's disease. Search for a dose-response relationship. Arch Neurol, 43: 774-778.
39. GOLBE LI, DAVIS PH, SCHOENBERG BS, DUVOISIN RC. (1988). Prevalence and natural history of progressive supranuclear palsy. Neurology, 38: 1031-1034.
40. GOLBE LI, RUBIN RS, CODY RP et al. (1996). Follow-up study of risk factors in progressive supranuclear palsy. Neurology, 47: 148- 154.
41. GORELL JM, RYBICKI BA, JOHNSON CC, PETERSON EL. (1999). Smoking and Parkinson's disease: a dose-response relationship. Neurology, 52: 115-119.
42. GRAHAM JG, OPPENHEIMER DR. (1969). Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry, 32: 28-34.
43. GRANDINETTI A, MORENS DM, REED D, MAC EACHERN D. (1994). Propspective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol, 139: 1129-1138.
44. GRANIERI E, CARRERAS M, CASETFA I et al. (1991). Parkinson's disease in Ferrarra, Italy, 1967 through 1987. Arch Neurol, 48: 854-857.
45. Gu M, GASH MT, COOPER JM et al. (1997). Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord, 12: 418-422.
46. HANNA PA, JANKOVIC J, KIRKPATRICK JB. (1999). Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol, 56: 90-94.
47. HARHANGI BS, DE RIJK MC, VAN DUIJN CM, VAN BROECKHOVEN C, HOFMAN A, BRETELER MM. (2000). ApoE and the risk of Parkinson's disease with or without dementia in a population-based study. Neurology, 54: 1272-1276.
48. HOEHNICKA J, PEREZ-TUR J, BARABASH A et al. (1999). The Tau gene A0 allele and progressive supranuclear palsy. Neurology, 53: 1219-1225.
49. JANSON AM, FUXE K, GOLDSTEIN M. (1992). Differential effects of acute and chronic nicotine treatment on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dine) induced degeneration of nigrosriatal dopamine neurons in the black mouse. Clin Invest, 70: 232-238.
50. JENDROSKA K, HOFFMANN O, SCHELOSKY L, LEES AJ, POEWE W, DANIEL SE. (1994). Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome. J Neurol Neurosurg Psychiatry, 57: 1249-1251.
51. KITADA T, ASAKAWA S, HATTORI N et al. (1998). Mutations inthe Parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 393: 605-608.
52. KLOCKGETHER T, LODTKE R, KRAMER B et al. (1998). The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain, 121: 589-600.
53. KRÜGER R, KUHN W, MOLLER T et al. (1998). Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet, 18: 106-108.
54. KRÜGER R, VIERA-SAECKER AMM, KUHN W et al. (1999). Increased susceptbility to sporadic Parkinson's disease by certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol, 45: 611-617.
55. KUIPER MA, VISSER JJ, BERGMANS PLM, SCHELTENS P, WOLTERS EC. (1994). Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J Neurol Sci, 121: 46-49.
56. KUOPIO AM, MARTILLA RJ, HELENIUS H, RINNE UK. (1999). Environmental risk factors in Parkinson's disease. Mov Disord, 14: 928-939.
57. LANTOS PL. (1998). The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol, 57: 1099-1111.
58. LITVAN I, AGID Y, JANKOVIC J et al. (1996a). Accuracy of clinical criteria for the diagnosis of pregressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 46: 922-930.
59. LITVAN I, MANGONE CA, McKEE A et al. (1996b). Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Nearosurg Psychiatry, 61: 615-620.
60. LOHMANN E, DURR A, BRICE A. (2002). Dernirès nouvelles de la génétique de la maladie de Parkinson. Rev Neurol, 158: 763-766.
61. MAGGI S, ZUCCHETTO M, GRIGOLETTO F. (1994). The Italian longitudinal study on aging (ILSA): design and methods. Aging Clin Exp Res, 6: 464-473.
62. MANUBENS JM, MARTINEZ-LAGE JM, LACRUZ F et al. (1995). Prevalence of Alzheimer disease and other dementing disorders in Pamplona, Spain. Neuroepidemiology, 14: 155-164.
63. MARAGANORE DM, ANDERSON DW, BOWER JH, MCDONNELL SK, ROCCA WA. (1999). Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota. Neurology, 53: 1342-1344.
64. MARDER K, TANG MX, MEJLA H et al. (1996). Risk of Parkinson's disease among firstdegree relatives: a community-based study. Neurology, 47: 155-160.
65. MASLIAH E, ROCKENSTEIN E, VEINBERGS I et al. (2000). Dopaminergic loss and inclusion body formation in α-synucléine mice: implications for neurodegenerative disorders. Science, 287: 1265-1269.
66. MCCRANK E. (1990). PSP risk factors. Neurology, 40: 1637.
67. MORRIS HR, VAUGHAN JR, DATTA SR et al. (2000). Multiple system atrophy/progressive supranuclear palsy: alpha-synuclein, synphifin, tau and apo E. Neurology, 55: 1918-1920.
68. NATH U, BEN-SHLOMO Y, THOMSON HR, WOOD NW, LEES AJ, BURN DJ. (2001). The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the United kingdom. Brain, 124: 1438-1449.
69. NEE LE, GOMEZ MR, DAMBRIOSA J, BALE S, ELDRIDGE R, POLINSKY RJ. (1991). Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res, 1: 9-13.
70. OZAWA T, TAKANO H, ONODERA O et al. (1999). No mutation in the entire coding region of the α-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neursci Lett, 270: 110-112.
71. PAULSON GW. (1992). Addiction to nicotine is due to high intrinsec levels of dopamine. Med Hypothesis, 38: 206-207.
72. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al. (1997). Mutation in the alpha-synuclein gene identified in families with parkinson's disease. Science, 276: 2045-2047.
73. PRIYADARSHI A, KHUDER SA, SCHAUB EA, PRIYADARSHI SS. (2001). Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res, 86: 122-127.
74. QUINN NP. (1989). Multiple system atrophythe nature of the beast. J Neurol Neurosurg Psychiatry, 52: 78-89.
75. RAJPUT AH, UITTI RJ, STERN W, LAVERTY W. (1986). Early onset Parkinson's disease in Saskatchewan. Environmental considerations for etiology. Can J Neurol Sci, 13: 312-316.
76. ROCCA WA, BOWER JH, MCDONNELL SK, PETERSON BJ, MARAGANORE DM. (2001). Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology, 57: 462-7.
77. ROJO A, PERNAUTE RS, FONTAN A et al. (1999). Clinical genetics of familial progressive supranuclear palsy. Brain, 122: 1233-1245.
78. SANTACRUZ P, UTTL B, LITVAN I, GRAFMAN J. (1998). Progressive supranuclear palsy. A survey of the disease course. Neurology, 50: 1637-1647.
79. SCHRAG A, BEN-SHLOMO Y, QUINN NP. (1999). Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet, 354: 1771-1775.
80. SCHULZ JB, KLOCKGETHER T, PETERSEN D et al. (1994). Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123 IBZM-SPECT. J Neurol Neurosurg Psychiatry, 57: 1047-1056.
81. TAN EK, KHAJAVI M, THORNBY JI, NAGAMITSU S, JANKOVIC J, ASHIZAWA T. (2000). Variability and validity of polymorphism association studies in Parkinson's disease. Neurology, 55: 533-538.
82. TANNER CM. (1992). Epidemiology of Parkinson's disease. Neurol Clin, 10: 317-329.
83. TANNER CM, CHEN B, WANG WZ et al. (1987). Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci, 14: 419-423.
84. TANNER CM, CHEN B, WANG A et al. (1989). Environmental factors and Parkinson's disease: a case-control study in China. Neurology, 39: 660-664.
85. TANNER CM, OTTMAN R, GOLDMAN SM et al. (1999). Parkinson's disease in twins. J Am Med Assoc, 281: 341-6.
86. TESTA D, FILIPPINI G, FARINOTTI M, PALAZZINI E, CARACENI T. (1996). Survival in multiple system atrophy: a study of prognosis factors in 59 cases. J Neurol, 243: 401-404.
87. TISON F. (1998). Maladie de Parkinson et syndromes parkinsoniens. In: Rascol A, editor. La maladie de Parkinson. Paris; Masson (Acanthe): 41-61.
88. TISON F, DARTIGUES JF, DUBES F, ZUBER M, ALPEROVITCH A, HENRY P. (1994). Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. Acta Neurol Scand, 90: 111-115.
89. TISON F, LETENNEUR L, DJOSSOU F, DARTIGUES JF. (1996). Further evidence of increased risk of mortality of Parkinson's disease. J Neurol Neurosurg Psychiatry, 60: 592-593.
90. TISON F, YEKHLEF F, CHRYSOSTOME V, SOURGEN C. (2000). Prevalence of multiple system atrophy. Lancet, 355.: 495-496.
91. TISON F, CHRYSOSTOME V, YEKHLEF F, SOURGEN C. BALDI L IGUES JF. (2001). Epidemiology of multiple system atrophy: a risk factor study in Aquitaine, France. Neurology, 56(sul 3): A117.
92. TRENKWALDER C, SCHWARZ J, GEBHARD J et al. (1995). Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol, 52: 1017-1022.
93. TZOURIO C, ROCCA WA, BRETELER MD et al. (1997). Smoking habits and Parkinson's disease. An age-dependant risk effect? Neurology, 49: 1267-1272.
94. VANACORE N, BONIFATI V, FABBRINI G et al. (2000). Smoking habits in multiple system atrophy and progressive supra nuclear palsy. Neurology, 54: 114-119.
95. WENNING GK, WAGNER S, DANIEL SE, QUINN NP. (1993). Multiple system atrophy: sporadic or familial? Lancet, 342: 681.
96. WENNING GK, TISON F, BEN-SHLOMO Y, DANIEL SE, QUINN NP. (1997). Multiple system atroophy: a meta-analysis of 203 pathologically proven cases. Mov Disord, 12: 133-147.
97. WERMUTH L, JOENSEN P, BÜNGER N, JEUNE B. (1997). High prevalence of Parkinson's disease in the Faroe islands. Neurology. 49: 426-432.
98. YAMASHITA T, ANDO Y, OBAYASHI K et al. (2000). Oxidative injury is present in Purkinje cells in patients with olivopontocerebellar atrophy. J Neurol Sci, 175: 107-110.
99. ZHANG ZX, ROMAN GC. (1993). Worldwilde occurrence of Parkinson's disease: an updated review. Nettroepid, 12: 195-208.